Literature DB >> 32147003

The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?

Samira S Farouk1, Joshua L Rein2.   

Abstract

Calcineurin inhibitors (CNIs) are both the savior and Achilles' heel of kidney transplantation. Although CNIs have significantly reduced rates of acute rejection, their numerous toxicities can plague kidney transplant recipients. By 10 years, virtually all allografts will have evidence of CNI nephrotoxicity. CNIs have been strongly associated with hypertension, dyslipidemia, and new onset of diabetes after transplantation-significantly contributing to cardiovascular risk in the kidney transplant recipient. Multiple electrolyte derangements including hyperkalemia, hypomagnesemia, hypercalciuria, metabolic acidosis, and hyperuricemia may be challenging to manage for the clinician. Finally, CNI-associated tremor, gingival hyperplasia, and defects in hair growth can have a significant impact on the transplant recipient's quality of life. In this review, the authors briefly discuss the pharmacokinetics of CNI and discuss the numerous clinically relevant toxicities of commonly used CNIs, cyclosporine and tacrolimus.
Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Calcineurin inhibitors; Cyclosporine; Drug toxicity; Kidney transplantation; Tacrolimus

Year:  2020        PMID: 32147003      PMCID: PMC7080294          DOI: 10.1053/j.ackd.2019.08.006

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  157 in total

1.  The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups.

Authors:  L M Mancinelli; L Frassetto; L C Floren; D Dressler; S Carrier; I Bekersky; L Z Benet; U Christians
Journal:  Clin Pharmacol Ther       Date:  2001-01       Impact factor: 6.875

2.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

3.  Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine.

Authors:  C H Barton; N D Vaziri; D C Martin; S Choi; S Alikhani
Journal:  Am J Med       Date:  1987-10       Impact factor: 4.965

4.  Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients.

Authors:  L C Rump; V Oberhauser; E Schwertfeger; L Speidel; L Zimmerhackl; G Kirste; W Grotz
Journal:  J Hypertens       Date:  2000-08       Impact factor: 4.844

5.  Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.

Authors:  Norihiko Tsuchiya; Shigeru Satoh; Hitoshi Tada; Zhenhua Li; Chikara Ohyama; Kazunari Sato; Toshio Suzuki; Tomonori Habuchi; Tetsuro Kato
Journal:  Transplantation       Date:  2004-10-27       Impact factor: 4.939

6.  Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake.

Authors:  L W Elzinga; S Rosen; W M Bennett
Journal:  J Am Soc Nephrol       Date:  1993-08       Impact factor: 10.121

7.  Arginine feeding modifies cyclosporine nephrotoxicity in rats.

Authors:  L De Nicola; S C Thomson; L M Wead; M R Brown; F B Gabbai
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

8.  Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia.

Authors:  Tom Nijenhuis; Joost G J Hoenderop; René J M Bindels
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

Review 9.  Dyslipidemia following kidney transplantation: diagnosis and treatment.

Authors:  Stéphanie Badiou; Jean-Paul Cristol; Georges Mourad
Journal:  Curr Diab Rep       Date:  2009-08       Impact factor: 4.810

10.  NaCl cotransporter abundance in urinary vesicles is increased by calcineurin inhibitors and predicts thiazide sensitivity.

Authors:  Omar A Z Tutakhel; Arthur D Moes; Marco A Valdez-Flores; Marleen L A Kortenoeven; Mathijs V D Vrie; Sabina Jeleń; Robert A Fenton; Robert Zietse; Joost G J Hoenderop; Ewout J Hoorn; Luuk Hilbrands; René J M Bindels
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240

View more
  14 in total

Review 1.  AKAP Signaling Islands: Venues for Precision Pharmacology.

Authors:  Mitchell H Omar; John D Scott
Journal:  Trends Pharmacol Sci       Date:  2020-10-17       Impact factor: 14.819

Review 2.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

3.  Cyclosporine A-Induced Conchal Hyperplasia with Nasal Obstruction in a Patient with Membranous Nephropathy.

Authors:  Frank-Peter Tillmann; Ana Harth; Fedai Özcan; Achim Jörres
Journal:  Am J Case Rep       Date:  2022-05-21

Review 4.  Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies.

Authors:  George Robinson; Ines Pineda-Torra; Coziana Ciurtin; Elizabeth C Jury
Journal:  J Clin Invest       Date:  2022-01-18       Impact factor: 14.808

5.  Calcineurin inhibitors target Lck activation in graft-versus-host disease.

Authors:  Nicole M Carter; Joel L Pomerantz
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

Review 6.  Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus.

Authors:  Wei Sun; Pengchong Li; Jianping Cai; Jie Ma; Xuan Zhang; Yong Song; Yudong Liu
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

7.  An Integrated Transcriptomic Approach to Identify Molecular Markers of Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.

Authors:  Erika T Rhone; Elissa Bardhi; Sai Vineela Bontha; Patrick D Walker; Jorge A Almenara; Catherine I Dumur; Helen Cathro; Daniel Maluf; Valeria Mas
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

8.  The Effect of Maintenance Treatment with Twice-Daily or Prolonged Once-Daily Tacrolimus Formulation on Visual Evoked Potentials in Stable Kidney Transplant Recipients.

Authors:  Aureliusz Kolonko; Małgorzata Jurys; Sebastian Sirek; Tomasz Dwulit; Dorota Pojda-Wilczek; Andrzej Więcek
Journal:  J Clin Med       Date:  2020-06-11       Impact factor: 4.241

Review 9.  B Cells in Primary Membranous Nephropathy: Escape from Immune Tolerance and Implications for Patient Management.

Authors:  Benjamin Y F So; Desmond Y H Yap; Tak Mao Chan
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

10.  Q134R: Small chemical compound with NFAT inhibitory properties improves behavioral performance and synapse function in mouse models of amyloid pathology.

Authors:  Pradoldej Sompol; Jenna L Gollihue; Susan D Kraner; Irina A Artiushin; Ryan A Cloyd; Emad A Chishti; Shon A Koren; Grant K Nation; Jose F Abisambra; Orsolya Huzian; Lajos I Nagy; Miklos Santha; Laszlo Hackler; Laszlo G Puskas; Christopher M Norris
Journal:  Aging Cell       Date:  2021-06-12       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.